Properties (67)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Alexion_Pharmaceuticals
gptkb:MedImmune |
| gptkbp:clinicalTrials |
mental health
biomarkers chronic disease management gene therapy personalized medicine rare diseases autoimmune diseases community health programs diagnostic tools preventive health measures immunization programs cardiovascular diseases biologics cardiovascular health global health initiatives infectious diseases immunotherapy pharmacogenomics public health research targeted therapy pain management vaccine development cancer treatments women's health cancer prevention health economics health technology assessment respiratory diseases respiratory health health disparities research gastrointestinal diseases patient-reported outcomes real-world evidence health outcomes research cell therapy COVID-19 vaccines therapeutic devices clinical pharmacology metabolic diseases quality of life studies vaccine safety studies vaccine efficacy studies diabetes treatments epidemiology studies neurology treatments |
| gptkbp:collaborations |
government agencies
|
| gptkbp:communityEngagement |
health initiatives
|
| gptkbp:employees |
over 1,000
|
| gptkbp:focus |
biopharmaceuticals
|
| gptkbp:founded |
2000
|
| gptkbp:headquarters |
gptkb:Mississauga,_Ontario,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
AstraZeneca Canada Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
gptkb:Canada
|
| gptkbp:parentCompany |
gptkb:AstraZeneca_PLC
|
| gptkbp:partnerships |
various research institutions
|
| gptkbp:products |
vaccines
oncology drugs cardiovascular drugs respiratory drugs |
| gptkbp:regulatoryCompliance |
gptkb:Health_Canada
|
| gptkbp:researchAndDevelopment |
clinical trials
|
| gptkbp:sustainability |
environmental responsibility
|
| gptkbp:website |
www.astrazeneca.ca
|